ClinicalTrials.gg
CompletedNCT03642028Updated Nov 5, 2026

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

A Phase 4 interventional study of Suvorexant and Placebo in Sleep Initiation and Maintenance Disorders and Stress Disorders, Posttraumatic, sponsored by VA Office of Research and Development. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now CompletedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders — 5 open to participants now, 5 under way, 1 of them phase 3. suvorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
8th of 38
145 · median 44
Started
2019
with 5 others
Phase 4
22 of 38
2 open now
Registered
20th of 38
by date
Lead sponsor
2 of 38
VA Office of Research and Development

Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, this one is the 8th largest by enrollment, is one of 6 that started in 2019, is one of 22 in phase 4, and was the 20th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

5 of the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About suvorexant

suvorexant: first FDA approval 2014 (BELSOMRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Post-traumatic stress disorder (PTSD) is a common consequence of combat that can result in trauma-related hyperarousal and sleep disturbances. Poor sleep, one of the most common complaints in Veterans with PTSD, can be distressing, impair concentration and memory, and contribute to physical health conditions, such as metabolic syndrome, inflammation, and cardiovascular disease. The orexin neuropeptide system underlies both sleep and stress reactivity. Suvorexant, a drug that reduces orexin, improves sleep in civilians, but has not yet been tested in Veterans with PTSD. This study will test whether suvorexant can improve sleep disturbances and PTSD symptoms in Veterans. Suvorexant may benefit Veterans by improving sleep quickly while also reducing PTSD symptoms over the long term, and with fewer side effects that were common in previous medications used to treat these conditions. Improving Veterans' sleep and PTSD symptoms could lead to better emotional and physical well-being, quality of life, relationships, and functioning.

Read the detailed description

The investigators propose a multi-site parallel group, randomized, double-blind, placebo-controlled Phase IV clinical trial to test the efficacy and safety of suvorexant on trauma-related sleep disturbance and PTSD symptoms in Veterans. The investigators will use a flexible dose design of suvorexant with a 2-week titration followed by a 10-week steady-dose phase. The investigators predict that suvorexant, as compared to placebo, will result in a greater decrease in insomnia on the Insomnia Severity Index (ISI) over the 12-week trial. The investigators also predict that suvorexant, as compared to placebo, will result in a greater reduction in non-sleep PTSD symptoms in the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSMV) CAPS-5 over the 12-week trial. Secondarily, the investigators will examine potential objectively measured wrist actigraphy as a biological mechanism of clinical improvement with as well as concomitant effects on PTSD-related nightmares using the Pittsburgh Sleep Quality Index-PTSD addendum (PSQI-A). Pending a significant effect of suvorexant on PTSD, the investigators will perform exploratory analyses to evaluate whether sleep improvement mediates the effect of suvorexant on PTSD symptoms. The investigators will also examine safety and tolerability of suvorexant compared to placebo (including depression, mood, vigor, suicidality, and daytime somnolence, psychomotor vigilance, and functional disability). Results from this study will provide substantive rationale for the use of Suvorexant in the treatment of Veterans with these concerns. This study will be the first to examine a selective orexin-receptor antagonist in a Veteran sample with PTSD. Suvorexant is an accessible, non-stigmatized medication whose use and safety has been well-established in non-mental-health settings. It has outstanding promise for treating common and distressing symptoms in Veterans as well as civilians with trauma-related sleep disturbance and PTSD.

03

Conditions studied

  • Sleep Initiation and Maintenance Disorders
  • Stress Disorders, Posttraumatic

Keywords

  • Sleep Initiation and Maintenance Disorders
  • Stress Disorders, Posttraumatic
  • Suvorexant
  • Veterans
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with a history of US military service, capable of reading and understanding English, and able to provide written
  • Criterion A event meets criteria
  • Post-traumatic stress disorder (PTSD) symptoms >3 months duration as indexed by a CAPS-5 12 and a partial PTSD diagnosis at screening
  • Insomnia indicated by an ISI score > 14
  • Subjects on non-exclusionary medications must be on a stable dose for at least 4 weeks prior to randomization, which includes the Selective Serotonin Reuptake Inhibitors (SSRIs) e.g.:

    • Sertraline
    • Paroxetine
    • Fluoxetine
    • Fluvoxamine
    • Citalopram
    • Escitalopram
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs), e.g.:

    • Desvenlafaxine
    • Duloxetine
    • Levomilnacipran
    • Venlafaxine
  • For subjects who are in psychotherapy, treatment must be stable for 6 weeks
  • Women of must not be pregnant or have plans for pregnancy or breastfeeding during the study and must use a medically acceptable method of , e.g.:

    • oral
    • implantable
    • injectable
    • transdermal contraceptive
    • intrauterine device
    • double-barrier method
  • Sleep apnea score \<30; if screening indicates mild or moderate sleep apnea (score between 5 and 30), referral will be provided

Exclusion criteria

Exclusion Criteria:

  • , Fifth Edition (DSM-5) alcohol, marijuana, and/or other drug use disorder in the last 3 months

    • Mild alcohol use not meeting criteria for moderate or severe use disorder may be allowed on a case-by-case basis
    • Mild or moderate marijuana use disorder may be allowed on a on a case-by-case basis
  • Manic or psychotic episode in the last 5 years
  • Exposure to trauma in the last 3 months
  • Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS) or increased risk of suicide that necessitates additional therapy or inpatient treatment
  • Pre-existing severe sleep apnea (score >30) in the absence of adherence to effective treatment (such as CPAP or oral device) or positive screen for severe sleep apnea by type III device (score > 30)
  • Neurologic disorder or systemic illness affecting CNS function
  • Chronic or unstable medical illness including:

    • unstable angina
    • myocardial infarction within the past 6 months
    • congestive heart failure
    • preexisting hypotension or orthostatic hypotension
    • heart block or arrhythmia
    • chronic renal or hepatic failure
    • pancreatitis
    • severe
  • History of severe traumatic brain injury
  • Mild cognitive impairment assessed by the
  • Pregnancy, breastfeeding and/or refusal to use effective (for women)
  • Narcolepsy
  • Previous adverse reaction to a hypnotic
  • Current use of benzodiazepines, strong inhibitors, or Digoxin

Prohibited:

  • Benzodiazepines
  • Strong CYP3A inhibitors
  • Digoxin
  • Furthermore, CNS depressants (e.g., benzodiazepines, opioids, alcohol) increase the risk of CNS depression when co-administered with suvorexant and will not be allowed for safety reasons.
  • Since metabolism by CYP3A is the major elimination pathway for suvorexant, concomitant use of suvorexant with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan), moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil), or strong CYP3A inducers (e.g., rifampin, carbamazepine and phenytoin) will not be allowed.
  • All concomitant medication use will be monitored and documented
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Suvorexant

    Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.

    Drug: Suvorexant

  • Placebo comparator
    Identical Placebo

    Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.

    Other: Placebo

Interventions

  • Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.

    Also known as: Belsomra

  • OtherPlacebo

    Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI)

    The ISI is a specific index of perceived insomnia severity. Areas assessed include problems with sleep onset, sleep maintenance, and early morning awakening; dissatisfaction with sleep; interference with daily functioning; impact on quality of life; and worry about sleep problems.

    Time frame: Change from baseline to week 12

  2. Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 is a 30-item interview that is the gold standard assessment for PTSD. The CAPS-5 provides a dimensional and categorical measure of PTSD, and incorporates frequency and intensity of symptoms into a single severity score. The CAPS-5 will determine a threshold for PTSD severity (past week) at baseline (excluding change in item #20 falling and staying asleep). Possible scores range from 0 to 80. All trained and certified CAPS-raters will function independently and will not be involved in recruitment, study coordination, or evaluation of side effects.

    Time frame: Change from baseline to week 12

Secondary outcomes

  1. Wrist Actigraphy

    Sleep wake schedule will be monitored with wrist actigraphy (Micro Motionlogger, Ambulatory Monitoring, Inc.). The actigraph provides continuous activity data using a battery-operated wristwatch-size microprocessor that senses motion with a three axis accelerometer. High-resolution data will be down-sampled to one-minute sample intervals for conventional actigraphic sleep-wake estimation and analyzed using ActionW-2 (Ambulatory Monitoring, Inc.) software. Sleep efficiency, sleep maintenance, total sleep time and wake after sleep onset will be used as secondary measures of sleep.

    Time frame: Change from 1 week at baseline, and weeks 4, 8, and 12

  2. Pittsburgh Sleep Quality Index-PTSD Addendum (PSQI-A)

    PSQI-A will be used to assess disruptive nocturnal behaviors related to PTSD, including nightmares, hot flashes and episodes of terror during sleep. Scores ranges from 0 (normal) to 21 (severe). The investigators plan to evaluate nightmares as a secondary outcome.

    Time frame: Change in PTSD-related nightmares across the 12 week trial

Other outcomes

  1. Clinical Global Impression (CGI)

    The Clinician and patient reports of improvement on the CGI (depression, mood, vigor, suicidality, daytime somnolence, and functional disability rating scales.) The CGI measures psychiatric treatment response by evaluating global severity of illness and change in the clinical condition over time. It consists of 3 global subscales: Severity of Illness, Global Improvement, and Efficacy Index. Item 1 is rated on a seven-point scale (1=normal to 7=extremely ill); item 2 on a seven-point scale (1=very much improved to 7=very much worse); and item 3 on a four-point scale (from 'none' to 'outweighs therapeutic effect'). The CGI will be used as a secondary measure of remission (i.e., CGI-I of 1 "very much improved" or 2 "much improved").

    Time frame: Change across the 12 week trial

07

Study locations

4 sites
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jun 2026, 82 months.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 82 months is above that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2018
First posted
Aug 22, 2018
StartActual
Aug 30, 2019
Primary completionActual
Jun 30, 2026was Dec 2025
CompletionActual
Jun 30, 2026was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 5, 2026
Primary completion
Dec 31, 2025→Jun 30, 2026 (actual)
Nov 5, 2026
Study completion
Dec 31, 2025→Jun 30, 2026 (actual)
Nov 5, 2026
Enrollment
190 (estimated)→145 (actual)
Nov 5, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedMen and Women, age range of 18 to 75,women with a history of US military service, capable of reading and understanding English, and able to provide written informed consent
  • EditedPost-traumatic stress disorder (PTSD) symptoms >3 months duration as indexed by a CAPS-5 12 and a partial PTSD diagnosis at screening
Exclusion criteria
  • EditedDiagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) alcohol, marijuana, and/or other drug use disorder in the last 3 months
Nov 5, 2026
Documents
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Dec 31, 2025→Jun 30, 2026 (now actual)
    Study completion Dec 31, 2025→Jun 30, 2026 (now actual)
    Enrollment 190 (estimated)→145 (actual)
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedMen and Women, age range of 18 to 75,women with a history of US military service, capable of reading and understanding English, and able to provide written informed consent
    • EditedPost-traumatic stress disorder (PTSD) symptoms >3 months duration as indexed by a CAPS-5 12 and a partial PTSD diagnosis at screening
    Exclusion criteria
    • EditedDiagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) alcohol, marijuana, and/or other drug use disorder in the last 3 months
    + 5 other changes: verification date, description, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03642028
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Aug 30, 2019
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Nov 5, 2026

Study contacts

Sabra S Inslicht, PhD
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion